|
1
|
Pfister DG, Spencer S, Brizel DM, Burtness
B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele
DW, et al: Head and neck cancers, version 1.2015. J Natl Compr Canc
Netw. 13:847–855; quiz 856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vermorken J, Mesia R, Rivera F, Remenar E,
Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D,
et al: Platinum-based chemotherapy plus cetuximab in head and neck
cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hitt R, Irigoyen A, Cortes-Funes H, Grau
JJ, García-Sáenz JA and Cruz-Hernandez JJ: Spanish Head and Neck
Cancer Cooperative Group (TTCC): Phase II study of the combination
of cetuximab and weekly paclitaxel in the first-line treatment of
patients with recurrent and/or metastatic squamous cell carcinoma
of head and neck. Ann Oncol. 23:1016–1022. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Price KA and Cohen EE: Mechanisms of and
therapeutic approaches for overcoming resistance to epidermal
growth factor receptor (EGFR)-targeted therapy in squamous cell
carcinoma of the head and neck (SCCHN). Oral Oncol. 51:399–408.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hasegawa T, Tanakura M, Takeda D,
Sakakibara A, Akashi M, Minamikawa T and Komori T: Risk factors
associated with distant metastasis in patients with oral squamous
cell carcinoma. Otolaryngol Head Neck Surg. 152:1053–1060. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liao CT, Wang HM, Chang JT, Ng SH, Hsueh
C, Lee LY, Lin CH, Chen IH, Huang SF and Yen TC: Analysis of risk
factors for distant metastases in squamous cell carcinoma of the
oral cavity. Cancer. 110:1501–1508. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lim JY, Lim YC, Kim SH, Kim JW, Jeong HM
and Choi EC: Predictive factors of isolated distant metastasis
after primary definitive surgery without systemic treatment for
head and neck squamous cell carcinoma. Oral Oncol. 46:504–508.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakamoto Y, Matsushita Y, Yamada SI,
Yanamoto S, Shiraishi T, Asahina I and Umeda M: Risk factors of
distant metastasis in patients with squamous cell carcinoma of the
oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol.
121:474–480. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chakraborty S, Filippi CG, Wong T, Ray A,
Fralin S, Tsiouris AJ, Praminick B, Demopoulos A, McCrea HJ,
Bodhinayake I, et al: Superselective intraarterial cerebral
infusion of cetuximab after osmotic blood/brain barrier disruption
for recurrent malignant glioma: Phase I study. J Neurooncol.
128:405–415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grisanti S, Amoroso V, Buglione M, Rosati
A, Gatta R, Pizzocaro C, Ferrari VD and Marini G: Cetuximab in the
treatment of metastatic mucoepidermoid carcinoma of the salivary
glands: A case report and review of literature. J Med Case Rep.
2:3202008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Black KL and Ningaraj NS: Modulation of
brain tumor capillaries for enhanced drug delivery selectively to
brain tumor. Cancer Control. 11:165–173. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Benavente S, Huang S, Armstrong EA, Chi A,
Hsu KT, Wheeler DL and Harari PM: Establishment and
characterization of a model of acquired resistance to epidermal
growth factor receptor targeting agents in human cancer cells. Clin
Cancer Res. 15:1585–1592. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hatakeyama H, Cheng H, Wirth P, Counsell
A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough
WG, et al: Regulation of heparin-binding EGF-like growth factor by
miR-212 and acquired cetuximab-resistance in head and neck squamous
cell carcinoma. PLoS One. 5:e127022010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kimura I, Kitahara H, Ooi K, Kato K,
Noguchi N, Yoshizawa K, Nakamura H and Kawashiri S: Loss of
epidermal growth factor receptor expression in oral squamous cell
carcinoma is associated with invasiveness and
epithelial-mesenchymal transition. Oncol Lett. 11:201–207. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmitz S, Bindea G, Albu RI, Mlecnik B
and Machiels JP: Cetuximab promotes epithelial to mesenchymal
transition and cancer associated fibroblasts in patients with head
and neck cancer. Oncotarget. 6:34288–34299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pyo SW, Hashimoto M, Kim YS, Kim CH, Lee
SH, Johnson KR, Wheelock MJ and Park JU: Expression of E-cadherin,
P-cadherin and N-cadherin in oral squamous cell carcinoma:
Correlation with the clinicopathologic features and patient
outcome. J Craniomaxillofac Surg. 35:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wheeler SE, Suzuki S, Thomas SM, Sen M,
Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY
and Grandis JR: Epidermal growth factor receptor variant III
mediates head and neck cancer cell invasion via STAT3 activation.
Oncogene. 29:5135–5145. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wheeler SE, Morariu EM, Bednash JS, Otte
CG, Seethala RR, Chiosea SI and Grandis JR: Lyn kinase mediates
cell motility and tumor growth in EGFRvIII-expressing head and neck
cancer. Clin Cancer Res. 18:2850–2860. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yanamoto S, Yamada S, Takahashi H, Naruse
T, Matsushita Y, Ikeda H, Shiraishi T, Seki S, Fujita S, Ikeda T,
et al: Expression of the cancer stem cell markers CD44v6 and ABCG2
in tongue cancer: Effect of neoadjuvant chemotherapy on local
recurrence. Int J Oncol. 44:1153–1162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
La Fleur L, Johansson AC and Roberg K: A
CD44high/EGFRlow subpopulation within head and neck cancer cell
lines shows an epithelial-mesenchymal transition phenotype and
resistance to treatment. PLoS One. 7:e440712012. View Article : Google Scholar : PubMed/NCBI
|
